Hi folks, I am publishing my blog a day early due to the holiday weekend.  Here are the top regulatory stories for this week: On Monday Dova Pharmaceuticals announced the FDA completed their Priority Review and approved DOPTELET (avatrombopag) for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to[…]